TLR2 and cancer: Strategies to increase response rates to agonists combined with checkpoint blockade therapy include cancer vaccines, radiation, Toll-like receptor agonists, etc. As this trial continues, Arm 9 aims to enroll patients with TNBC and identify the clinical response of BMS-986178, nivolumab, cyclophosphamide and DPV-001, an autophagosome cancer vaccine containing 25 putative cancer antigens, damage-associated molecular patterns (DAMPs), heat shock proteins, and TLR2, 3, 4, 7 and 9 agonists [97].